{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:57:54Z","timestamp":1792511874979,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Orthopaedic Science"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1007\/s00776-009-1431-y","type":"journal-article","created":{"date-parts":[[2010,2,11]],"date-time":"2010-02-11T08:40:30Z","timestamp":1265877630000},"page":"104-111","source":"Crossref","is-referenced-by-count":28,"title":["Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors"],"prefix":"10.1016","volume":"15","author":[{"given":"Takahiro","family":"Tajino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Ichi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Ichi","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s00776-009-1431-y_bb0005","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(85)91288-7","article-title":"Ifosfamide\/mesna and encephalopathy","volume":"1","author":"Cantwell","year":"1985","journal-title":"Lancet"},{"key":"10.1007\/s00776-009-1431-y_bb0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF00405909","article-title":"Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma","volume":"100","author":"Heim","year":"1981","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1007\/s00776-009-1431-y_bb0015","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1200\/JCO.1997.15.6.2378","article-title":"High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies \u2014 dose-response and schedule dependence","volume":"15","author":"Patel","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1007\/s00776-009-1431-y_bb0020","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1200\/JCO.1987.5.8.1303","article-title":"Irreversible encephalopathy with ifosfamide\/mesna","volume":"5","author":"Salloum","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1007\/s00776-009-1431-y_bb0025","first-page":"727","article-title":"Phase II study of ifosfamide in cervical cancer","volume":"70","author":"Meanwell","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1007\/s00776-009-1431-y_bb0030","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1600-0404.1992.tb05136.x","article-title":"Encephalopathy in ifosfamide-treated patients","volume":"86","author":"Merimsky","year":"1992","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s00776-009-1431-y_bb0035","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/08880018909034311","article-title":"Fatal encephalopathy with ifosfamide\/mesna","volume":"6","author":"Verdeguer","year":"1989","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1007\/s00776-009-1431-y_bb0040","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(86)92227-0","article-title":"Dechloroethylation of ifosfamide and neurotoxicity","volume":"2","author":"Goren","year":"1986","journal-title":"Lancet"},{"key":"10.1007\/s00776-009-1431-y_bb0045","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s002280050102","article-title":"Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy","volume":"50","author":"K\u00fcpfer","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1007\/s00776-009-1431-y_bb0050","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/oxfordjournals.annonc.a010686","article-title":"Ifosfamide encephalopathy and methylene-blue: a case report","volume":"7","author":"Alonso","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1007\/s00776-009-1431-y_bb0055","first-page":"751","article-title":"Phase I clinical trial of isophosphamide (NSC-109724)","volume":"59","author":"Cohen","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"10.1007\/s00776-009-1431-y_bb0060","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00001813-200404000-00006","article-title":"Ostermann. H, Schiel X. Incidence and severity of ifosfamide-induced encephalopathy","volume":"15","author":"Rieger","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1007\/s00776-009-1431-y_bb0065","first-page":"921","article-title":"Unexpected toxicity in patients treated with iphosphamide","volume":"32","author":"Van Dyk","year":"1972","journal-title":"Cancer Res"},{"key":"10.1007\/s00776-009-1431-y_bb0070","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/15563658908994426","article-title":"Ifosfamide encephalopathy","volume":"27","author":"Danesh","year":"1989","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.1007\/s00776-009-1431-y_bb0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clon.2006.11.003","article-title":"Ifosfamide encephalopathy","volume":"19","author":"Ajithkumar","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1007\/s00776-009-1431-y_bb0080","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.4065\/81.10.1361","article-title":"Psychiatric adverse effects of corticosteroids","volume":"81","author":"Warrington","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1007\/s00776-009-1431-y_bb0085","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1097-0142(19891115)64:10<2010::AID-CNCR2820641007>3.0.CO;2-O","article-title":"Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma","volume":"64","author":"Gastrointestinal Tumor Study Group","year":"1989","journal-title":"Cancer"},{"key":"10.1007\/s00776-009-1431-y_bb0090","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.1989.7.1.126","article-title":"Response to ifosfamide and mesna: 124 previously treated patients with metastatic or resectable sarcoma","volume":"7","author":"Antman","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1007\/s00776-009-1431-y_bb0095","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/1097-0142(19910701)68:1<72::AID-CNCR2820680114>3.0.CO;2-#","article-title":"Ifosfamide extrapyramidal neurotoxicity","volume":"68","author":"Anderson","year":"1991","journal-title":"Cancer"},{"issue":"suppl 4","key":"10.1007\/s00776-009-1431-y_bb0100","first-page":"68","article-title":"Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules","volume":"17","author":"Antman","year":"1990","journal-title":"Semin Oncol"},{"key":"10.1007\/s00776-009-1431-y_bb0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0090-8258(91)90344-5","article-title":"Ifosfamide-induced neurotoxicity","volume":"42","author":"Curtin","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1007\/s00776-009-1431-y_bb0110","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.1986.4.8.1253","article-title":"Central nervous system toxicity following the treatment of pediatric patients with ifosfamide\/mesna","volume":"4","author":"Pratt","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1007\/s00776-009-1431-y_bb0115","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/0277-5379(86)90368-8","article-title":"Prediction of ifosfamide\/mesna associated encephalopathy","volume":"22","author":"Meanwell","year":"1986","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1007\/s00776-009-1431-y_bb0120","first-page":"1457","article-title":"Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum (II) therapy","volume":"47","author":"Goren","year":"1987","journal-title":"Cancer Res"},{"key":"10.1007\/s00776-009-1431-y_bb0125","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.1990.8.8.1399","article-title":"Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumor","volume":"8","author":"Pratt","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1007\/s00776-009-1431-y_bb0130","first-page":"753","article-title":"Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma","volume":"49","author":"Lind","year":"1989","journal-title":"Cancer Res"},{"key":"10.1007\/s00776-009-1431-y_bb0135","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00432-005-0679-7","article-title":"Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge","volume":"131","author":"Karin","year":"2005","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1007\/s00776-009-1431-y_bb0140","first-page":"1","article-title":"Cisplatin nephrotoxicity: experimental and clinical studies","volume":"37","author":"Daugaard","year":"1990","journal-title":"Dan Med Bull"},{"key":"10.1007\/s00776-009-1431-y_bb0145","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1054\/bjoc.1999.0917","article-title":"Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature","volume":"82","author":"Pelgrims","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1007\/s00776-009-1431-y_bb0150","first-page":"4636","article-title":"Treatment of ifosfamide encephalopathy with intravenous thiamin","volume":"9","author":"Buesa","year":"2003","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Orthopaedic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0949265815320236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0949265815320236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00776-009-1431-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T22:02:18Z","timestamp":1558821738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0949265815320236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0949265815320236"],"URL":"https:\/\/doi.org\/10.1007\/s00776-009-1431-y","relation":{},"ISSN":["0949-2658"],"issn-type":[{"value":"0949-2658","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}